Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

Original publication

DOI

10.1126/science.1086916

Type

Journal article

Journal

Science

Publication Date

27/06/2003

Volume

300

Pages

2036 - 2039

Keywords

AIDS Vaccines, Academies and Institutes, Biotechnology, Clinical Trials as Topic, Drug Design, Drug Evaluation, Preclinical, Drug Industry, Financial Support, Global Health, HIV Infections, HIV-1, Humans, Intellectual Property, International Cooperation, Multicenter Studies as Topic, Private Sector, Public Policy, Public Sector, Research Support as Topic, Vaccination